her 2 receptor  (ATCC)

Journal: bioRxiv

Article Title: Pharmacological Characterization of SDX-7320/Evexomostat: a Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-Tumor and Anti-Metastatic Activity

doi: 10.1101/2024.02.29.582701

Figure Lengend Snippet: A. A549 xenograft model: SDX-7320 and SDX-7539 were injected IV, Q4D or QOD, respectively, into nude mice (ten/group) with established A549 tumors (treatment was initiated when tumors were between 100 and 200 mm 3 ). TNP-470 was injected IV every other day. Statistical analysis was carried out by two-way ANOVA with Sidack’s multiple comparisons test (GraphPad,v9.0). B. EO771 syngeneic model of TNBC: ovariectomized mice with orthotopic EO771 tumors were dosed with SDX-7320 (Eight mice/group, 24 mg/kg, SC, Q4D; total of four doses) after which tumors were dissected and fixed in buffered formalin for histology and IHC. Statistical analysis of tumor volume was carried out by two-way ANOVA with Sidack’s multiple comparisons test; N=8 mice/group (GraphPad,v9.0). C, D. Immunostaining of formalin-fixed, paraffin-embedded tumor tissue with antibodies against Ki67 or CD31. The density of staining (# of positive cells/tissue area) was quantified using Aperio software (Leica Inc). Statistical analysis was carried out by unpaired t-test (GraphPad,v9.0). E. MDA-MB-231 tumors were grown in chick embryos (inoculated on day E9, then dissected and weighed on day E19). Treatment with vehicle, paclitaxel (2.1 μg, every other day, four doses), SDX-7320 (15, 90 μg, every four days, two doses) was initiated on day E11. Statistical analysis was conducted using one-way ANOVA with Dunnett’s multiple comparisons test (GraphPad v9.0) F. MDA-MB-231 tumor blood vessel density on day E18 for vehicle, paclitaxel (2.1 μg), SDX-7320 (15, 90 μg). G. MDA-MB-231 tumor metastasis into the lower CAM after treatment with vehicle, paclitaxel (2.1 μg, QOD, four doses), SDX-7320 (15, 90 μg, every four days, two doses). H. B16-F10 syngeneic model of lung metastases: treatment with vehicle, TNP-470 (30 mg/kg, IP, QOD) or SDX-7320 (25 mg/kg, SC, Q4D) was initiated one day after tumor cells were administered via tail vein injection (eight mice/group). I. BT-474 xenograft tumor growth (model of HR+/HER2+ breast cancer; eight mice/group) after SDX-7320 (6, 12 mg/kg, SC, every four days). Statistical analysis of tumor volume was conducted using a mixed-effects model with Dunnett’s multiple comparisons (GraphPad v9.0) J. Volcano plot of differentially expressed genes (DEGs) from tumors in SDX-7320 (12 mg/kg)-treated mice (N=5) relative to tumors from vehicle-treated mice (N=6). K. Results of pathway enrichment analysis (Enricher) conducted on DEGs (n=268) from SDX-7320 (12 mg/kg)-treated tumors relative to tumors from vehicle-treated mice (only pathways with enrichment scores with p≤0.01 are shown). L. Heat maps of the top 20 DEGs from two selected pathways (Hallmark Inflammatory Response, Hallmark Hypoxia) that were significantly altered in tumors from SDX-7320-treated mice.

Article Snippet: BT-474 HER-2+, estrogen receptor (ER)+ BC Xenograft Model Female Athymic Nude mice were obtained from Charles River and implanted with subcutaneous, slow-release estrogen (90-day, 0.72 mg β-estradiol; Innovative Research of America).

Techniques: Injection, Immunostaining, Formalin-fixed Paraffin-Embedded, Staining, Software

Journal: Cell Reports Medicine

Article Title: Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response

doi: 10.1016/j.xcrm.2023.101251

Figure Lengend Snippet:

Article Snippet: Human epidermal growth factor receptor 2 (HER-2), clone GE001 , Dako, Santa Clara, CA, USA, , HER-2, HercepTest™ Kit.

Techniques: Amplification, In Situ, Hybridization, RNA Sequencing Assay, Software